Conversely, a gradual decrease of SOX9 has been related to a progression to advanced stage, high Gleason grade, and metastatic growth in ERG-positive cancers, and these effects were strictly limited to the subset of prostate cancers harboring PTEN deletions [28]. The gene discussed is SOX9; the disease is prostate carcinoma.